View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
July 16, 2019

China’s pharma industry sees a drop of 28.1% in deal activity in Q2 2019

China’s pharma industry saw a drop of 28.1% in overall deal activity during Q2 2019, when compared with the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 23 deals worth $1.92bn were announced in Q2 2019, compared to the last four-quarter average of 32 deals.

Venture financing was the leading category in the quarter with 16 deals which accounted for 69.6% of all deals.

In second place was M&A with six deals, followed by private equity with one transactions, respectively accounting for 26.1% and 4.4% of overall deal activity in the country’s pharma industry during the quarter.

In terms of value of deals, M&A was the leading deal category in China’s pharma industry with total deals worth $1.48bn, while venture financing and private equity deals totalled $429.66m and $14.85m, respectively.

China pharma industry deals in Q2 2019: Top deals

The top five pharma deals accounted for 85.5% of the overall value during Q2 2019.

The combined value of the top five pharma industry deals stood at $1.64bn, against the overall value of $1.92bn recorded for the quarter. The top announced China pharma industry deal tracked by GlobalData in Q2 2019 was Cordlife Group’s $911.98m acquisition of Global Cord Blood.

In second place was the $375m asset transaction with Eli Lilly and by Eddingpharm and in third place was Deyi Capital, Gaoke Xinyi Capital, Gongqingcheng Hanren, Huaxin Century Investment Group, Loyal Valley Capital, Nanjing Gaoke Xinchuang Investment, Qianlong Capital, SDIC Unity Capital, Shiyu Capital Group and Yuansheng Venture Capital’s $170.83m venture financing of Allist Shanghai Pharmaceutical Technology.

The $108.55m acquisition of Chengdu List Pharmaceutical by Jinzhou Aohong Pharmaceutical and 3E Bioventures, Decheng Capital, Oriza Seed Venture Capital, SDIC Fund Management, Sherpa Healthcare Partners and South China Venture Capital’s venture financing of EpimAb Biotherapeutics for $74m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU